CQDM/CIHR Collaborative Funding Program to Accelerate Drug Discovery in Personalized Medicine

CIHR is pleased to be partnering with the Quebec Consortium for Drug Discovery (CQDM) in a new collaborative funding program in personalized medicine that aims to accelerate drug discovery and drug development. The novelty of this new program lies in the combination of the respective strengths of the partners: academic research for CIHR and translational industrial research for CQDM. It will namely offer the opportunity to Small and Medium Enterprises (SMEs) to collaborate with academia to develop new cutting-edge technologies, computational tools and devices in personalized medicine in order to bring solutions to the most pressing needs in biopharmaceutical research and healthcare. Successful applicants will also benefit from CQDM's mentorship program which brings industrial support and expertise to the projects and helps better align the research with the needs of the pharmaceutical industry.

In an effort to bring solutions which will address the most urgent needs of biopharmaceutical research, CQDM and CIHR will fund research projects focused on the invention and development of next-generation of technologies, computational tools and devices in the following research areas:

  • cancer;
  • infection and immunity;
  • neurodegeneration affecting cognition.

Entitled CQDM/CIHR Collaborative Funding Program to Accelerate Drug Discovery in Personalized Medicine, this program extends to scientific and technical fields directly related to biopharmaceutical R&D and all disciplines that could provide new technologies and devices for biopharmaceutical research.

This new program builds upon the extensive initiatives and multiple projects funded as part of the CIHR Personalized Medicine Signature Initiative. Deadline for letters of intent is June 27, 2014. For more information on the program, please visit CQDM's website.

Date modified: